Drug Controller General of India (DCGI) has finally given marketing approval to Ranbaxy for its new drug Synriam which is having anti-malarial property.Synriam is a Fixed Dose Combination (FDC) of “arterolane maleate (150 mg) and piperaquine phosphate (750 mg). Arterolane was invented by the researchers from University of Nebraska (USA), Monash University (Australia), the Swiss Tropical Institute & Hoffman La Roche. The initial research was funded and co- ordination by the non-profit Medicines for Malaria Venture (MMV), which also have its Indian patent for the drug – IN 245779. The Phase III clinical trials were conducted successful and reportedly last year and Ranbaxy had announced the launch of the drug on April 25, 2012 – World Malaria Day.